MEDI 109 |
| Iron depletion using iron chelators is known as one of the most efficient strategies for the treatment of excess iron-caused diseases. The structurally novel ligand, NETA possessing both a macrocyclic cavity and an acyclic pendant metal binding group has been designed for therapeutic and diagnostic applications. We previously reported that NETA possesses great potential for antibody targeted radiation cancer therapy and MRI. We have screened NETA and NETA along with other potential iron depletion agents for iron depletion in Hela cells. NETA was found to be effective in depleting iron in Hela cells displaying significantly enhanced inhibition compared to DFO which is clinically available for treatment of iron overloading diseases. Synthesis and biological evaluation of NETA and NETA analogues as an iron depletion agent in various cell lines will be reported. |
|
Poster Session
7:00 PM-9:00 PM, Sunday, August 19, 2007 BCEC -- Exhibit Hall - B2, Poster
Division of Medicinal Chemistry |